Article Text

other Versions

Download PDFPDF
Presence of antiphospholipid antibodies in COVID-19: case series study
  1. Luis M Amezcua-Guerra1,
  2. Gustavo Rojas-Velasco2,
  3. Malinalli Brianza-Padilla1,
  4. Armando Vázquez-Rangel2,
  5. Ricardo Márquez-Velasco1,
  6. Francisco Baranda-Tovar2,
  7. Rashidi Springall1,
  8. Hector Gonzalez-Pacheco2,
  9. Yaneli Juárez-Vicuña1,
  10. Claudia Tavera-Alonso2,
  11. Fausto Sanchez-Muñoz1,
  12. Marisol Hernández-Salas2
  1. 1Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
  2. 2Intensive Care Unit, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
  1. Correspondence to Dr Luis M Amezcua-Guerra, Departamento de Inmunología, Instituto Nacional de Cardiologia Ignacio Chavez, 14080 Tlalpan, Mexico; lmamezcuag{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated coagulopathy are particularly worrisome in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), as these diseases carry an increased risk of thrombotic complications. Mathian et al recently reported the clinical course of COVID-19 in a series of 17 patients with SLE under chronic hydroxychloroquine therapy.1 Of note, only one patient (6%) presented thrombosis despite the fact that four patients (24%) had a history of secondary APS, and five patients (29%) were receiving oral anticoagulants. Antiphospholipid (aPL) antibodies were not measured in these patients during active SARS-CoV-2 infection.1

The American Society of Hematology recently stated that ‘at the current time, there are only very limited data on aPL antibodies in COVID-19 and it is unclear if they represent an epiphenomenon or are actually involved in any haemostatic abnormalities seen in COVID-19 disease’.2 Furthermore, almost all the available information refers to the lupus anticoagulant, with frequencies ranging from 45% to 87%.3 4 This paucity of data led us to test a panel of aPL antibodies in blood specimens from 21 patients hospitalised in the intensive care unit between 12 and 19 …

View Full Text


  • Contributors All the authors made contributions in the acquisition, analysis and interpretation of data. In addition, they revised it critically for important intellectual content and gave their final approval of the version published.LMAG additionally conceived and designed the study and drafted the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles